SynthesisAesthetic plastic surgery2026
Efficacy and Safety of LetibotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Systematic Review and Meta-Analysis of RCTs.
Synthesis in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Ready-To-Use AbobotulinumtoxinA More Effective Than OnabotulinumtoxinA for Glabellar Lines? A Randomized, Controlled, Triple-Blinded Clinical Trial.Journal of cosmetic dermatology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotulinum toxin type A injections are widely used for the aesthetic treatment of glabellar lines; however, data on the efficacy and safety of newer formulations remain limited.
aimThis systematic review and meta-analysis aims to assess the efficacy and safety of the novel botulinum toxin LetibotulinumtoxinA-wlbg compared to placebo for treating moderate-to-severe glabellar lines.
methodsA systematic literature search was conducted to identify randomized controlled trials (RCTs) comparing LetibotulinumtoxinA-wlbg with placebo in adults. A meta-analysis was performed using random-effects models, and the Cochrane RoB-2 tool was used to assess the risk of bias.
resultsThree RCTs including 1272 patients were analyzed. LetibotulinumtoxinA-wlbg was significantly more effective than placebo for the primary outcome, the composite responder rate at week 4 (risk ratio [RR] = 59.47; 95% CI: 14.95, 236.52). Sustained efficacy was observed at weeks 12 and 16, with significant improvements also seen in investigator-assessed, subject-assessed, and psychological outcomes. The safety analysis revealed no significant increase in the risk of serious, non-serious, or overall treatment-emergent adverse events.
conclusionsLetibotulinumtoxinA-wlbg is an efficacious and well-tolerated treatment for moderate-to-severe glabellar lines. The therapeutic effect is durable, with statistically significant efficacy maintained at 12 and 16 weeks post-treatment. Treatment results in a significant improvement in patients' psychological well-being related to their facial appearance. The safety profile is favorable, with no statistically significant increase in the risk of serious or non-serious adverse events compared to placebo. Further research, including direct head-to-head trials, is warranted to establish its comparative effectiveness. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41501424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.